French-Swedish Executive Seminar On Value-Based Healthcare - A5

FRENCH–SWEDISH EXECUTIVE SEMINAR ON VALUE-BASED HEALTHCAREPARIS, JUNE 13TH, 2016

Programme & participants

3BUSINESS SWEDEN | FRENCH–SWEDISH EXECUTIVE SEMINAR ON VALUE-BASED HEALTHCARE |

DEAR FRIENDS,France and Sweden have a longstanding close relationship. The first trade agreement between our countries was signed as early as 1498. Trade remains a central ingredient of our bilateral relations. Today France ranks among the ten most important markets for Swedish imports and exports. Swed-ish companies in France employ around 100 000 persons. An important theme in our bilateral cooperation is research and innovation.

As Sweden’s Ambassador to France I am very happy to host this executive seminar aiming towards increased intellectual and commercial exchange in the important field of value-based health care. Our two countries both rank highly in in-ternational comparisons of health care systems and we share many challenges and opportunities. One of these challenges is the growth in demand for, and cost of, health care services. We also see that the quality and outcome of investments in health care can vary greatly between different care facili-ties and geographical locations. A common opportunity we share is the increasingly involved and well-informed patient ready to be an engaged partner and co-producer in the development of health care. These aspects have the potential to fundamentally change the way we think about quality and efficiency in care.

I look forward to deepen and develop the partnership be-tween Sweden and France in the field of health. By working together we can both develop our national health systems and find ways to tackle common health challenges to im-prove health outcomes that matter to all.

Yours sincerely, Veronika Wand-Danielsson Ambassador of Sweden to France

WELCOMING WORDS

VERONIKA WAND-DANIELSSON Ambassador of Sweden to France

4 | BUSINESS SWEDEN | FRENCH–SWEDISH EXECUTIVE SEMINAR ON VALUE-BASED HEALTHCARE

ORGANIZERS AND PARTNERS


PROGRAMME

FRENCH-SWEDISH EXECUTIVE SEMINAR ON VALUE-BASED HEALTHCARE PARIS, JUNE 13TH, 2016

08.30–09.00 REGISTRATION AND COFFEE

09.00–09.10 WELCOME NOTE H.E. Veronika Wand-Danielsson, Swedish Ambassador to France

09.10–09.25 OPENING SPEECH SWEDEN Mr. Gabriel Wikström, Swedish Minister for Health Care, Public Health and

Sport

09.25–09.40 OPENING SPEECH FRANCE Ms. Anne-Marie Armanteras de Saxcé, Director General, Directorate of

Healthcare Supply (DGOS), Ministry of Social Affairs and Health

09.40–10.00 HEALTHCARE OF THE FUTURE Prof. Martin Ingvar, Deputy Vice-Chancellor at Karolinska Institutet and Dr.

Christina Åkerman, President of International Consortium for Health Outcomes Measurement (ICHOM)


PROGRAMME

THEME 1 INCENTIVES FOR IMPROVING HEALTH OUTCOMES AND INCREASING EFFICIENCY

10.00–10.15 CONNECTING QUALITY OF CARE TO FINANCIAL INCENTIVES Mr. Félix Faucon, Inspector General at the General inspectorate for social and health affairs and member of the European Commission health systems performance assessment group

10.15–10.30 DRIVING QUALITY BY PUBLIC BENCHMARKING Mr. Jens Wilkens, Health Policy Analyst, OECD

10.30–11.10 PANEL DISCUSSION AND Q&A Mr. Félix Faucon, Mr. Jens Wilkens, Mr. Philippe Durand, Mr. Hervé Gourgouillon

11.10–11.30 COFFEE BREAK

THEME 2 IMPROVING OUTCOMES THROUGH INNOVATION AND

COLLABORATION11.30–12.40 PERSONALIZED AND INNOVATIVE CANCER MANAGEMENT Prof. Alexander M.M. Eggermont, MD, PhD, Director General of Gustave

Roussy Comprehensive Cancer Center

MEDICAL OUTCOMES AS THE GUIDING PRINCIPLE Dr. Barbro Fridén, MD, PhD, CEO of Sahlgrenska University Hospital

PANEL DISCUSSION AND Q&A Prof. Alexander M.M. Eggermont, Dr. Barbro Fridén, Mr. Stéphane Le Roy

12.40–13.00 CONCLUDING SESSION Key findings and open discussion on possibilities for increased collaboration,

held by Prof. Martin Ingvar and Business Sweden

13.00–14.00 LUNCH


SPEAKERS AND PANELISTS

MS. ANNE-MARIE ARMANTERAS DE SAXCÉDirector General, Directorate of Healthcare Supply (DGOS), Ministry of Social Affairs and Health

Anne-Marie Armanteras de Saxcé has been appointed as such, since 4th of April 2016.

The General Directorate for Health Care Services is in charge of the definition and governance of the healthcare services supply policy, its strategic management and its coordination (between hospi-tal and out-patient care), together with Regional Health agencies (“ARS”) and specialized state agencies.

Prior to this, she joined the Regional Health Agency for “Ile-de-France” in 2013, where she first occupied the position of Director for “health care services” and subsequently was nominated Director for healthcare and medico-social issues, as from 18th of November 2013.

Graduated from the National School for Public Health ‘”EHESP”, Anne-Marie Armanteras de Saxcé held outstanding management positions in the hospital sector.

MR. GABRIEL WIKSTRÖMSwedish Minister for Health Care, Public Health and Sport

Gabriel Wikström was appointed Minister for Health care, Public health and Sport in October 2014 and is a member of the Social Democratic Party.

His policy focus areas include health equity, equal access to good quality health care and a free and independent sports movement that gives all population groups access to sports and physical activi-ties. Wikström began his career in the Swedish Social Democratic Youth League and was national chairman before being appointed cabinet minister in 2014.

Sweden is one of the most prosperous and healthy countries in the world. But there are health disparities between various groups nonetheless. This is serious, but what is even more troubling is that these disparities are growing. To turn this trend around, the Govern-ment has set a goal to eliminate avoidable health inequalities within a generation.


PROF. DR. MARTIN INGVARProf. Martin Ingvar, MD, PhD, is Deputy Vice-Chancellor for future health care services at Karolinska Institutet and the Barbro and Ber-nard Osher Professor of Integrative Medicine.

His research is on systematic improvement of health care and subjective wellbeing. He co-founded International Consortium for Health care outcome measurements (ICHOM) in 2012.


MR. FÉLIX FAUCONSince the 1st of July 2015: Inspector general at the General inspector-ate for social and health affairs.

As well as these professional activities: Senior lecturer (health eco-nomics) in Sciences Po Paris – school of political science ; member of the expert group “health systems performance assessment” set up by the European commission and chaired by Mrs. Olivia Wigzell (SE).

Previously: During 6,5 years deputy CEO of the General directorate for health system organization (Ministry of health).



MR. JENS WILKENSJens Wilkens is Health Policy Analyst at the OECD Health Division. Until recently he was Health Economist at the Swedish National Board for Health and Welfare and lecturer in courses on health systems development and health care financing at both Uppsala University and Karolinska Institute. Jens has worked in the WHO health financing programs in both Copenhagen and in Geneva with supporting countries building resource tracking systems and indica-tor packages for performance assessment. He has done extensive work on financing reform in health and related social services in a long list of European countries.

PROF. ALEXANDER M.M. EGGERMONTDirector General of Gustave Roussy Comprehensive Cancer Center, Cancer Campus Grand Paris, France.

Full Professor of Oncology (2012–20) at the Paris-Sud University in Paris, France. Full Professor of Surgical Oncology (2003-2016) as well as Endowed Professor of International Networking in Cancer Research (2011–2020) at Erasmus University MC Rotterdam. He holds the Joseph Maisin Chair in Oncology at Catholic University of Louvain in Belgium. PhD in tumor immunology at Erasmus University Rotterdam (1987) and is a Fellow of the NCI Surgery Branch, USA.

Specialties: Clinical specialties include immunotherapy, melanoma, sarcoma and regional therapy techniques as well as general drug de-velopment. Past Chair of the EORTC Melanoma Group, current Chair of the Adjuvant Therapy Committee EORTC MG. His basic research experience is in tumor immunology, advanced in vivo imaging mod-els and tumor pathophysiology.

Scientific Output: author or co-author of > 800 peer-reviewed pub-lications, book chapters and monographs. 35 PhD theses have origi-nated in his clinical, translational and basic research programs at the Erasmus University MC Rotterdam. H-index:76; >28000 citations.



DR. BARBRO FRIDÉNDoctor Barbro Fridén earned an MD degree in 1983. She has subse-quently specialised in Obstetrics and Gynaecology, focusing on re-productive medicine and IVF. In 1999, she completed her PhD thesis in human ovarian physiology. Dr. Fridén has for the past decade held several leading positions in Swedish healthcare in both public and private practices. She is currently the CEO of Sahlgrenska University Hospital. Preceding this, Dr. Fridén served as Director for the Chil-dren’s Hospital at Karolinska University Hospital.

Sahlgrenska University Hospital is one of northern Europe’s largest hospitals and is assigned more National Specialised Medical Care agreements than any other hospital in Sweden, including paediatric heart surgery and transplantation of heart, lung and liver. Sahlgren-ska University Hospital is one of six teaching hospitals with medical education in Sweden.

MR. STÉPHANE LE ROYStéphane Le Roy is the President of the Getinge Group in France, Italy and Iberia. He has dedicated his entire career to the field of medical technology, from biomedical equipment in imaging, steri-lization, to implantable medical devices. Prior to joining Getinge in 2012, Stéphane held several leadership positions in Marketing, Sales and Supply Chain within Siemens and GE Healthcare. Stéphane is a graduate of the engineering school Ecole des Ponts ParisTech.



MR. PHILIPPE DURANDPhilippe Durand joined Capio in 2003 as CFO for Capio France. He was appointed Regional Manager in 2011 and took over responsibility of Capio France as Business Area Manager in 2013.

He started his career in 1993 as auditor and advisor at Arthur Andersen, and then joined Infogrames Entertainment as Financial Controller from 1999 to 2003. Philippe graduated from EM Lyon Business School in 1992.

MR. HERVÉ GOURGOUILLONHervé Gourgouillon joined Diaverum France in March 2013. Hervé is 42 years old, father of 4 children, and based in Paris. Hervé is a graduate from Ecole Polytechnique and Mines de Paris, France (X-Mines, MSc degree). Hervé has a strong commercial and busi-ness experience from the healthcare industry in France. He joined Diaverum from Medtronic, where he held the position of Business Director Cardio Vascular. Before that he has held diverse business, marketing and sales positions in Medtronic and GE Healthcare - GE Medical Systems.

Sweden delivers world-class healthcare for everyone. Our achievement is based on innova-tive methods and products through close collaboration between care providers, academia and industry. Openness to new ideas, know ledge exchange, multi-disciplinary teams and an evidence-based approach brings high quality and a cost-efficient system.

www.symbiocare.org


ASTRAZENECAAt AstraZeneca, our purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve this is to put science at the centre of everything we do. It is this commitment that drives our ability to discover, develop and deliver the advancements the world needs in complex and difficult diseases like cancer, heart disease, diabetes, COPD and asthma.

For us, the discovery of medicines starts with our rare combination of scientific capabilities in small molecules and biologics, immuno-therapies, protein engineering technologies, oligonucleotides and devices. When combined with our strong focus on translational sci-ence and personalised healthcare, we believe that we have a unique and strong foundation for speeding novel, targeted therapies from biologic concept to care.

We know that the best science doesn’t happen in isolation - it hap-pens through collaboration. That is why we seek to work so exten-sively with scientific, academic and healthcare organisations around the world - from the earliest discovery work in our research labs, to our clinical trial programmes and to joint working with health care providers to achieve optimal treatment outcomes.

We also take smart risks in developing and applying new technolo-gies which help us to explore new mechanisms of action and create new types of treatments. It is when our scientists are empowered to follow these transformative areas of science that we see the most significant breakthroughs.

ORGANIZING PARTNERS

HEADQUARTERS2 Kingdom Street Paddington London W2 6BD T +44 (0)20 7604 8000 www.astrazeneca.com

LOCAL OFFICE AstraZeneca France Tour Carpe Diem 31, Place des Corolles 92400 Courbevoie T +33 (0)1 41 29 40 00

Mr. Jean-Yves Mairé Communications Director

jean-yves.maire@ astrazeneca.com

T +33 (0)1 41 29 45 02


CAPIOCapio is one of Europe’s leading health care companies with about 12,400 employees and 4.6 million patient visits per year and annual sales of 1.5 billion euros in 2015. Capio is active in Sweden, Norway, France and Germany with a broad range of medical, surgical and psychiatric care of high quality.

Capio in France operates 22 hospitals and specialist clinics in 7 re-gions across the country. Capio France has 5,300 full time employ-ees and more than 1000 affiliated doctors serving patients every day. Annual sales was 550 million euros in 2015. With its core focus on Modern Medicine and Rapid Recovery, Capio France position itself in the forefront of improving French healthcare supported by a significant investment program.

The pan European establishment allows for transfer of know-how and best practice between geographies, thus speeding up medical development and productivity gains.

Capio was founded in Gothenburg, Sweden in 1994. The company was de-listed from the Stockholm Stock Exchange in 2006 and has since then developed a company-wide medical strategy driven by an empowered organization geared to drive change in health care systems.

The focus of Modern Medicine and Modern Management position the Group to tackle the demographic challenges seen in the whole of Europe. Capio reentered the Stockholm Stock Exchange in mid-2015 to further support transparency and power to grow the company further.

ORGANIZING PARTNERS

HEADQUARTERSCapio AB Box 1064 SE-405 22 Gothenburg, Sweden Visiting address: Lilla Bommen 5 T +46 (0)31 732 40 00 www.capio.com

Mr. Thomas Berglund President and CEO Capio AB thomas.berglund@ capio.com

Mr. Philippe Durand Managing Director Capio France [email protected]

Mr. Francois Demesmay Deputy CMO Capio Group [email protected]

Mr. Henrik Brehmer SVP Group Communica-tion & Public Affairs henrik.brehmer@ capio.com

LOCAL OFFICE Capio France 113 Boulevard Stalingrad F-69100 Villeurbanne France T +33 (0)4 37 47 16 50


DIAVERUMDiaverum is a global renal care provider with a clear patient focus. As one of the world’s leading renal care providers we stand for excellent medical quality, renal care services and a patient-centred research.

Being product-independent also gives us the flexibility to offer individual treatments for the individual needs of our patients and by coordinating our patients’ healthcare needs, we are improving their quality of life.

At the same time we are creating value in the healthcare system by optimizing the use of healthcare budgets — for the benefit of the patient and the society.

Our experience in renal care dates back more than 25 years, when the first dialysis clinic was established.

Global presence Diaverum cares for close to 30 000 patients and 8 700 outpatients in more than 350 clinics across 20 countries: Argentina, Australia, Chile, France, Germany, Hungary, Italy, Kazakhstan, Lithuania, New Zealand, Poland, Portugal, Romania, Russia, Saudi Arabia, Spain, Sweden, Turkey, UK and Uruguay.

Diaverum in France Diaverum France was founded in 2007. Today, we care for more than 1 500 chronic patients in 17 kidney centers. Diaverum France services include preventive chronic kidney disease management in clinic and home dialysis, nocturnal dialysis, treatment of comorbidi-ties and multidisciplinary services (dietician, psychologist, social assistant etc).

ORGANIZING PARTNERS

HEADQUARTERSBox 4167 SE-227 22 Lund Sweden T +46 (0)46 287 30 00 F +46 (0)46 287 30 99 [email protected] www.diaverum.com

LOCAL OFFICE Diaverum France 24 A, rue Jean Baldassini 69007 Lyon T +33 (0)4 37 37 23 00 [email protected]

Mr. Hervé Gourgouillon Managing Director Diaverum France

[email protected]

T +33 (0)6 80 78 02 07


GETINGE GROUPGetinge is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within health-care and life sciences. The aim is to be the most desired medtech company in the world.

Every day, Getinge’s products contribute to saving lives and ensur-ing excellent care. The Group provides products and services for operating rooms, intensive-care units, hospital wards, sterilization departments, elderly care and for life science companies and institu-tions.

Getinge Group currently generates sales of more than SEK 30 billion and conducts sales via proprietary companies throughout the world. Production is conducted at facilities in Brazil, France, Canada, China, Germany, Poland, Sweden, Turkey, the UK and the US. In total, the Group has more than 15,000 employees in 40 countries.

The US and Canada is the largest region with 37% of sales, closely followed by Western Europe with 35%, and the rest of the world with 28%. 84% of sales are to hospitals, while elderly care accounts for 8% and the life science industry for 8%.

ORGANIZING PARTNERS

HEADQUARTERSGetinge Sverige AB Box 69 SE-305 05 Getinge T +46 (0)10 335 0000 [email protected] www.getinge.com

LOCAL OFFICE 7 Avenue du Canada 91940 Les Ulis T +33 (0)1 64 86 89 00

Mr. Alex Myers Group CEO and President, Getinge Group

Mr. Stéphane Le Roy President France Italy and Iberia Getinge Group


ORGANIZER

BUSINESS SWEDEN Business Sweden – The Swedish Trade and Invest Council helps Swedish companies reach their full international potential. We do this by offering strategic guidance and practical support, whether it is in Sweden or on location in one of the close to 50 markets where we are represented. In addition to our work with internationalisation and exports, our mission is also to attract foreign investments to Sweden, which brings competence, capital and innovation to Swedish companies.

Business Sweden is owned by the Swedish government and the industry, represented by the Ministry for Foreign Affairs and the Swedish Foreign Trade Association. The shared owner-ship provides access to contacts and networks at all levels.

REPRESENTATIVES

Ms. Annika Stål Senior Project Manager, France Co-moderator

Ms. Ebba G. Hult Head of Business Development Healthcare & Life Science Co- moderator

Mr. Robert Wentrup Trade Commissioner to France

HEADQUARTERSBusiness Sweden Box 240 SE-101 24 Stockholm, Sweden World Trade Center Klarabergsviadukten 70 T +46 (0)8 588 660 00 F +46 (0)8 588 661 90 [email protected] www.business-sweden.se

LOCAL OFFICE6 rue d’Uzès 75002 Paris T +33 (0)1 53 40 89 00 [email protected]

BUSINESS SWEDEN Box 240, SE-101 24 Stockholm, Sweden World Trade Center, Klarabergsviadukten 70 T +46 8 588 660 00 F +46 8 588 661 90 [email protected] www.business-sweden.se

French-Swedish Executive Seminar On Value-Based Healthcare - A5

Documents

Transcript of French-Swedish Executive Seminar On Value-Based Healthcare - A5